Dec 19 (Reuters) - TNF Pharmaceuticals Inc TNFA.O:
TNF PHARMACEUTICALS ANNOUNCES TRIAL TO EXPLORE EFFECTS OF LEAD CANDIDATE IN SARCOPENIA/FRAILTY INDUCED BY GLP-1 WEIGHT LOSS DRUGS
FULLY FUNDED STUDY TO EVALUATE WEGOVY AND OZEMPIC PATIENTS AT RISK FOR INCREASED INFLAMMATION ASSOCIATED WITH SARCOPENIC MUSCLE DETERIORATION
ENTERS COLLABORATIVE AGREEMENT WITH RENOVA HEALTH
Source text: ID:nBw9jKjzfa
Further company coverage: TNFA.O
((Reuters.Briefs@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。